These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35550167)

  • 1. Epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis synergises the anticancer effects of sorafenib in hepatocellular carcinoma.
    Wei T; Lin R; Fu X; Lu Y; Zhang W; Li Z; Zhang J; Wang H
    Pharmacol Res; 2022 Jun; 180():106244. PubMed ID: 35550167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.
    Liu J; Liu Y; Meng L; Liu K; Ji B
    Oncol Rep; 2017 Aug; 38(2):899-907. PubMed ID: 28627705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib.
    Houessinon A; François C; Sauzay C; Louandre C; Mongelard G; Godin C; Bodeau S; Takahashi S; Saidak Z; Gutierrez L; Régimbeau JM; Barget N; Barbare JC; Ganne N; Chauffert B; Coriat R; Galmiche A
    Mol Cancer; 2016 May; 15(1):38. PubMed ID: 27184800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of EGFR-KLF4 positive feedback loop results in acquired resistance to sorafenib in hepatocellular carcinoma.
    Pang L; Xu L; Yuan C; Li X; Zhang X; Wang W; Guo X; Ouyang Y; Qiao L; Wang Z; Liu K
    Mol Carcinog; 2019 Nov; 58(11):2118-2126. PubMed ID: 31465134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells.
    Cai H; Yang Y; Peng F; Liu Y; Fu X; Ji B
    Int J Med Sci; 2019; 16(12):1541-1548. PubMed ID: 31839741
    [No Abstract]   [Full Text] [Related]  

  • 6. CRNDE acts as an epigenetic modulator of the p300/YY1 complex to promote HCC progression and therapeutic resistance.
    Liu YC; Lin YH; Chi HC; Huang PS; Liao CJ; Liou YS; Lin CC; Yu CJ; Yeh CT; Huang YH; Lin KH
    Clin Epigenetics; 2022 Aug; 14(1):106. PubMed ID: 35999564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
    Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
    Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic Activation of Cytochrome P450 1A2 Sensitizes Hepatocellular Carcinoma Cells to Sorafenib.
    Zhang Y; Feng J; Mi Y; Fan W; Qin R; Mei Y; Jin G; Mao J; Zhang H
    Drug Metab Dispos; 2024 May; 52(6):555-564. PubMed ID: 38565301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
    Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing
    Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B
    Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
    Chen YT; Xiang D; Zhao XY; Chu XY
    Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABI2-mediated MEOX2/KLF4-NANOG axis promotes liver cancer stem cell and drives tumour recurrence.
    Chen J; Li H; Zhang B; Xiong Z; Jin Z; Chen J; Zheng Y; Zhu X; Zhang S
    Liver Int; 2022 Nov; 42(11):2562-2576. PubMed ID: 36017822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib.
    Niu LL; Cheng CL; Li MY; Yang SL; Hu BG; Chong CCN; Chan SL; Ren J; Chen GG; Lai PBS
    Cell Death Dis; 2018 Aug; 9(9):852. PubMed ID: 30154433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
    Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
    Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3'UTR polymorphisms of carbonic anhydrase IX determine the miR-34a targeting efficiency and prognosis of hepatocellular carcinoma.
    Hua KT; Liu YF; Hsu CL; Cheng TY; Yang CY; Chang JS; Lee WJ; Hsiao M; Juan HF; Chien MH; Yang SF
    Sci Rep; 2017 Jun; 7(1):4466. PubMed ID: 28667334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KAT6A is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP.
    Jin Y; Yang R; Ding J; Zhu F; Zhu C; Xu Q; Cai J
    Biochem Biophys Res Commun; 2021 Dec; 585():185-190. PubMed ID: 34808502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance.
    Xiang DM; Sun W; Zhou T; Zhang C; Cheng Z; Li SC; Jiang W; Wang R; Fu G; Cui X; Hou G; Jin GZ; Li H; Hou C; Liu H; Wang H; Ding J
    Gut; 2019 Oct; 68(10):1858-1871. PubMed ID: 31118247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.